Preclinical News and Research

RSS

Efficacy and safety data on linagliptin and investigational compound empagliflozin* in various diabetes subpopulations presented by Boehringer Ingelheim and Eli Lilly and Company

Boehringer Ingelheim and Eli Lilly and Company today announced they will feature five oral and 12 poster presentations for linagliptin and the investigational compound empagliflozin* at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD) which will take place in Barcelona, from 23 – 27 September. The presentations will add to the already existing body of data on safety and efficacy of these two compounds.

18 Sep 2013

GW Pharmaceuticals starts GWP42006 Phase 1 clinical trial for epilepsy treatment

GW Pharmaceuticals plc announced today it has commenced a Phase 1 clinical trial of product candidate GWP42006 for the treatment of epilepsy.

18 Sep 2013

SignaBlok's novel peptide inhibitor of TREM-1 suppresses cancer progression

SignaBlok, Inc., a Massachusetts-based biopharmaceutical company, today announced the successful in vivo proof of concept data that demonstrate that the company's novel mechanism-based, first-in-class peptide inhibitor of TREM-1 effectively suppresses cancer progression in mouse models of lung cancer and dramatically improves survival in septic mice.

18 Sep 2013

Cleveland Clinic creates spin-off company to develop vaccine for preventing breast cancer

Cleveland Clinic Innovations has created a spin-off company to develop a preventive breast cancer vaccine based on research from Cleveland Clinic's Lerner Research Institute.

18 Sep 2013

VBP15 drug shows early promise for treatment of Duchenne muscular dystrophy

A preclinical study led by researchers at Children's National Medical Center has found that a new oral drug shows early promise for the treatment of Duchenne muscular dystrophy.

18 Sep 2013

MR Solutions to release MR/PET and MR/SPECT scanners at WMIC

UK based MR Solutions continues to lead the technology revolution in pre clinical scanning with the launch of the first combined cryogen free, 3T, MR/PET and the first 3T, MR/SPECT scanners at the World Molecular Imaging Conference in Savannah this week (Sept 18-21st).

From MR Solutions 17 Sep 2013

Biocryst Wins Potentially $22M NIAID Contract To Develop Marburg Virus Disease Drug

...

17 Sep 2013

microRNA-486 found to be potent tumor-suppressor molecule in lung cancer

New research shows that microRNA-486 is a potent tumor-suppressor molecule in lung cancer, and that the it helps regulate the proliferation and migration of lung-cancer cells, and the induction of programmed cell death, or apoptosis, in those cells.

17 Sep 2013

FDA grants orphan drug designation to Soligenix’s SGX94 for treatment of Acute Radiation Syndrome

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that the Office of Orphan Products Development of the US Food and Drug Administration (FDA) has granted orphan drug designation to the active ingredient SGX94 for the treatment of acute radiation syndrome (ARS).

16 Sep 2013

MJFF Forms Research Tool Development Consortium For Parkinson's

...

13 Sep 2013

Columbia University launched three-year Doctor of Medicine program for PhD biological scientists

Columbia University College of Physicians and Surgeons (P&S) has launched a three-year Doctor of Medicine (MD) program for PhD-trained biological scientists. The accelerated curriculum prepares graduates for physician-scientist careers that combine their knowledge of fundamental biomedical science with an understanding of how diseases and their treatments affect humans.

13 Sep 2013

Cell Therapeutics agrees to sell 15,000 shares of Series 18 Preferred Stock to Quogue Capital

Cell Therapeutics, Inc. today announced that it has agreed to sell 15,000 shares of its Series 18 Preferred Stock directly to Quogue Capital LLC and an affiliate of Perceptive Advisors LLC in a registered direct offering conducted without an underwriter or placement agent for gross proceeds of approximately $15 million (the "Offering").

13 Sep 2013

Four new pre-clinical drug development projects at NIH develop treatment for rare disease

Four new pre-clinical drug development projects at the National Institutes of Health will target a form of blindness and diseases characterized by cardiac problems. The projects were selected for their potential to treat specific rare diseases and to help scientists uncover new information that can be shared with other researchers.

13 Sep 2013

Scottsdale Healthcare, TGen initiate Thunder God vine clinical trial in pancreatic cancer patients

Taking a page from Chinese herbal medicine, Scottsdale Healthcare and the Translational Genomics Research Institute today initiated the first-in-human clinical trial for pancreatic cancer patients using a compound derived from a plant known as "Thunder God vine."

13 Sep 2013

Research holds promise for developing treatments for retinitis pigmentos

One of the leading causes of inherited blindness in humans, retinitis pigmentosa, is analogous to retinal dystrophies that lead to blindness in dogs. Because of their similarities, identifying gene mutations underlying several types of canine retinal dystrophies has suggested courses for research on RP in humans. These advances are significant for both humans and dogs.

12 Sep 2013

Preclinical News and Research

Efficacy and safety data on linagliptin and investigational compound empagliflozin* in various diabetes subpopulations presented by Boehringer Ingelheim and Eli Lilly and Company

GW Pharmaceuticals starts GWP42006 Phase 1 clinical trial for epilepsy treatment

SignaBlok's novel peptide inhibitor of TREM-1 suppresses cancer progression

Cleveland Clinic creates spin-off company to develop vaccine for preventing breast cancer

VBP15 drug shows early promise for treatment of Duchenne muscular dystrophy

MR Solutions to release MR/PET and MR/SPECT scanners at WMIC

Biocryst Wins Potentially $22M NIAID Contract To Develop Marburg Virus Disease Drug

microRNA-486 found to be potent tumor-suppressor molecule in lung cancer

FDA grants orphan drug designation to Soligenix’s SGX94 for treatment of Acute Radiation Syndrome

MJFF Forms Research Tool Development Consortium For Parkinson's

Columbia University launched three-year Doctor of Medicine program for PhD biological scientists

Cell Therapeutics agrees to sell 15,000 shares of Series 18 Preferred Stock to Quogue Capital

Four new pre-clinical drug development projects at NIH develop treatment for rare disease

Scottsdale Healthcare, TGen initiate Thunder God vine clinical trial in pancreatic cancer patients

Research holds promise for developing treatments for retinitis pigmentos

High resolution of U‐SPECT/CT system helps perform kinetic analyses of viral spread in vivo

Astrazeneca Licenses Merck's Cancer Candidate MK-1775

Biogen Idec, Amicus Launch Parkinson's Collaboration

Bayer, Broad On Five-Year Mission To Search For Novel Cancer Therapeutics

Roche Signs Up To $422.5M Collaboration With Inovio

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics